Analysts are intrested in these 5 stocks: ( (KR) ), ( (MRK) ), ( (WDAY) ), ( (ABBV) ) and ( (LLY) ). Here is a breakdown of their recent ratings and the rationale behind them.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kroger Company is catching the attention of analysts with its impressive performance and strategic moves. Analyst Bill Kirk has upgraded Kroger’s stock to a ‘Buy’ with a new price target of $75, citing the company’s strong internal sales, cost control, and profit growth. Despite facing competition from giants like Walmart, Kroger has managed to improve its sales and profitability, particularly in the Food-at-Home sector. The company’s e-commerce growth and alternative profit streams are also noteworthy, making it a strong contender in the market.
Merck & Company, on the other hand, has seen a downgrade from ‘Buy’ to ‘Hold’ by analyst Luisa Hector. The downgrade reflects uncertainties around Merck’s growth profile, especially with the looming Keytruda patent expiry. While Merck has had a successful year in terms of pipeline news and deal-making, the long-term sales outlook remains uncertain. The company is encouraged to reinvest Keytruda cash flows into external assets to strengthen its growth prospects.
Workday is making strategic moves to stay relevant in the AI era, leading to an upgrade from ‘Underweight’ to ‘Hold’ by analyst Brent Bracelin. The company has been actively acquiring AI companies and introducing new pricing models to adapt to changing market dynamics. Despite facing execution risks, Workday’s efforts to diversify its offerings and improve its financial framework are seen as positive steps towards growth.
AbbVie has been upgraded to ‘Buy’ by analyst Luisa Hector, thanks to its strong growth outlook and successful navigation of drug patent expiries. The company’s focus on R&D and strategic acquisitions has bolstered its position in various sectors, including immunology and oncology. With high single-digit growth and strong cash flows, AbbVie is well-positioned for future success, warranting a premium valuation.
Eli Lilly & Co has been downgraded to ‘Hold’ by analyst Kerry Holford, despite its impressive performance in the obesity and diabetes markets. The downgrade comes as expectations for Lilly’s franchise have plateaued, and competition from Novo Nordisk intensifies. While Lilly’s R&D returns remain strong, the company faces challenges in maintaining its market lead and justifying its valuation premium.